Diffuse cutaneous systemic sclerosis treated with intravenous iloprost [10]

Clinical and Experimental Dermatology

Volumn 29, Issue 3, 2004, Pages 321-323

  Foti, C ^a   Cassano, N ^b   Conserva, A ^a   Coviello, C ^a   De Meo, M ^a   Vena, G A ^a  

^a UNIVERSITY OF BARI   (Italy)

^b LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; CELL NUCLEUS ANTIGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DNA ANTIBODY; ILOPROST; IMMUNOGLOBULIN A; NIFEDIPINE;

AGED; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DYSPNEA; ECHOCARDIOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; HYPERTENSION; LABORATORY TEST; LETTER; MALE; PRIORITY JOURNAL; PROGNOSIS; RAYNAUD PHENOMENON; SIDE EFFECT; SKIN BIOPSY; SKIN INDURATION; SPIROMETRY; SYSTEMIC SCLEROSIS; TELANGIECTASIA;

AGED; HUMANS; ILOPROST; INFUSIONS, INTRAVENOUS; MALE; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; VASODILATOR AGENTS;

EID: 2442670438     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2004.01529.x     Document Type: Letter

References (10)

1. Perez MI, Kohn SR. Systemic sclerosis. J Am Acad Dermatol 1993; 28: 525-47.
2. Clements P, Lachenbruch P, Siebold J et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 1281-5.
3. Leighton C. Drug treatment of scleroderma. Drugs 2001; 61: 419-22.
4. Sapadin AN, Fleischmajer R. Treatment of scleroderma. Arch Dermatol 2002; 138: 99-105.
5. Candela M, Pansoni A, Jannino L et al. Coagulative modifications in patients with systemic sclerosis treated with iloprost or nifedipine. Ann Ital Med Int 2001; 16: 170-4.
6. Pope J, Fenlon D, Thompson A et al. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2000: CD000953.
7. Bettoni L, Geri A, Airo P et al. Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years. Clin Rheumatol 2002; 21: 244-50.
8. Müller B, Witt W, McDonald FM. Iloprost: stable prostacyclin analogue. In: Rubanyi, GM, ed. Cardiovascular Significance of Endothelium-Derived Vasoactive Factors. Mount Kisco, NY: Futura Publishing Co., 1991.
9. Mittag M, Beckheinrich P, Haustein UF. Systemic sclerosis-related Raynaud's phenomenon: effects of iloprost infusion therapy on serum cytokine, growth factor and soluble adhesion molecule levels. Acta Derm Venereol 2001; 81: 294-7.
10. Scorza R, Caronni M, Mascagni B et al. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study. Clin Exp Rheumatol 2001; 19: 503-8.